Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.77 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | IL1B | P01584 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2383396 | 0.99 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2384336 | 0.94 | CRBN (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24938255 | 0.94 | CRBN (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382971 | 0.93 | DDB1 (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL2382665 | 0.93 | CRBN (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL2399619 | 0.93 | CRBN (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL2381756 | 0.92 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20118479 | 0.91 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5549995 | 0.91 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1424775 | 0.91 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | claimed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-3096142-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | Celgene Corporation (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160319005-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2016-11-03 | — | — | US | disclosed |
| US-9365640-B2 | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | CELGENE CORPORATION (US) | 2016-06-14 | — | — | US | disclosed |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2012-12-20 | — | — | US | disclosed |
| WO-2012149299-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORAITON (US) | 2012-11-01 | — | — | WO | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7091353-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319005-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | DDB1 946/4885CRBN 1/4885IKZF3 1416/4885 |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | DDB1 3650/4885CRBN 1511/4885IKZF3 2/4885 |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | DDB1 946/4885CRBN 1/4885IKZF3 1416/4885 |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, TNFRSF1A | DDB1 3627/4885CRBN 1695/4885IKZF3 2/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | DDB1 3650/4885CRBN 1511/4885IKZF3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.